Entering text into the input field will update the search result below

Agile Therapeutics updates Q2 guidance

  • Agile Therapeutics (NASDAQ:AGRX) updated its Q2 Twirla demand (total cycles) and operating expense guidance that was initially provided on May 24, 2022.
  • Twirla demand is now seen to be at the mid-point of the earlier provided range (20K-22K) of 21.0K-21.5K cycles which marks ~26-30% Q/Q growth.

Recommended For You

Comments (3)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

funny...i read it as sell it now...MAYBE buy it back when it's cheaper
Dobbs99 profile picture
The stock will be off to the races 😜

No doubt. Perhaps all those long term holders might get bought out at 90cents for a NICE 50% gain (from today).

About AGRX

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Agile Therapeutics, Inc.
Palisade Bio, Inc.
Hoth Therapeutics, Inc.
Biofrontera Inc.
IM Cannabis Corp.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.